The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31387920.
- Also identified by DOI 10.1158/0008-5472.CAN-18-3712 and PMC identifier 6801094.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immune system is a robust and often untapped accomplice of many standard cancer therapies. A majority of tumors exist in a state of immune tolerance where the patient's immune system has become insensitive to the cancer cells. Because of its lymphodepleting effects, chemotherapy has the potential to break this tolerance. To investigate this, we created a mathematical modeling framework of tumor-immune dynamics. Our results suggest that optimal chemotherapy scheduling must balance two opposing objectives: maximizing tumor reduction while preserving patient immune function. Successful treatment requires therapy to operate in a "Goldilocks Window" where patient immune health is not overly compromised. By keeping therapy "just right," we show that the synergistic effects of immune activation and chemotherapy can maximize tumor reduction and control. SIGNIFICANCE: To maximize the synergy between chemotherapy and antitumor immune response, lymphodepleting therapy must be balanced in a "Goldilocks Window" of optimal dosing.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/79/20/5302/F1.large.jpg.
Medical subject headings
- Antineoplastic Agents
- Cancer Vaccines
- Immune System
- Immunotherapy
- Models, Immunological
- Neoplasms
- Precision Medicine